Oncotarget

Research Papers:

The clinical value of lncRNA NEAT1 in digestive system malignancies: A comprehensive investigation based on 57 microarray and RNA-seq datasets

Dan-Dan Xiong, Zhen-Bo Feng, Wei-Luan Cen, Jing-Jing Zeng, Lu Liang, Rui-Xue Tang, Xiao-Ning Gan, Hai-Wei Liang, Zu-Yun Li, Gang Chen _ and Dian-Zhong Luo

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:17665-17683. https://doi.org/10.18632/oncotarget.14756

Metrics: PDF 1680 views  |   HTML 1759 views  |   ?  


Abstract

Dan-Dan Xiong1,*, Zhen-Bo Feng1,*, Wei-Luan Cen1, Jing-Jing Zeng1, Lu Liang1, Rui-Xue Tang1, Xiao-Ning Gan1, Hai-Wei Liang1, Zu-Yun Li1, Gang Chen1 and Dian-Zhong Luo1

1 Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, Zhuang, China

Correspondence to:

Zu-Yun Li, email:

Gang Chen, email:

Keywords: LncRNA, NEAT1, digestive system malignancies, clinical value, microarray and RNA-seq datasets

Received: October 22, 2016 Accepted: January 10, 2017 Published: January 19, 2017

Abstract

This comprehensive investigation was performed to evaluate the expression level and potential clinical value of NEAT1 in digestive system malignancies. A total of 57 lncRNA datasets of microarray or RNA-seq and 5 publications were included. The pooled standard mean deviation (SMD) indicated that NEAT1 was down-regulated in esophageal carcinoma (ESCA, SMD = -0.35, 95% CI: -0.5~-0.20, P < 0.0001) and hepatocellular carcinoma (HCC, SMD = -0.47, 95% CI: -0.60~-0.34, P < 0.0001), while in pancreatic cancer (PC), NEAT1 was up-regulated (SMD = 0.45, 95% CI: 0.2~0.71, P = 0.001). However, NEAT1 expression in gastric cancer (GC), colorectal cancer (CRC), biliary tract cancer (BTC) and gallbladder carcinoma (GBC) showed no significant difference between cancer and control groups. The pooled area under the curve values for ESCA, GC, CRC, PC and HCC were 0.60, 0.89, 0.81, 0.77 and 0.69, respectively. Furthermore, our result demonstrated that a high expression of NEAT1 predicted an unfavorable prognosis in patients with digestive system malignancies (HR: 1.50, 95% CI: 1.28-1.76, P < 0.0001). Our study suggests that NEAT1 may play different roles in the initiation and progression of digestive system cancers and could be a potential diagnostic and prognostic biomarker in patients with digestive system carcinomas. Further and stricter studies with a larger number of cases are necessary to strengthen our conclusions.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14756